Thanks to this 100% online Master’s Degree, you will master the most innovative diagnostic strategies for managing Cancer of Unknown Primary and optimize patient quality of life”

Tumors of unidentified origin represent a complex challenge in Oncology. In response, the scientific community has developed new detection strategies that contribute to personalized therapies and long-term patient well-being. Therefore, it is essential for physicians to stay at the forefront of the latest advances in molecular diagnostics, bioinformatics, and targeted therapies to increase early cancer detection accuracy.

To support this, TECH has created an exclusive Master’s Degree in Cancer of Unknown Primary. Designed by renowned specialists in the field, the syllabus delves into cutting-edge molecular biology tools, including liquid biopsies and sequencing platforms. In this way, graduates will develop advanced clinical skills to rigorously detect genetic alterations associated with these tumors. The program also equips physicians with the knowledge to optimize evidence-based clinical decision-making,. As such,  professionals will be able to perform a more precise selection of effective treatments tailored to each patient’s molecular profile.

Additionally, this degree adapts to physicians’ needs with a fully flexible 100% online format.  Available 24/7 and accessible from any device, it allows learners to progress at their own pace. TECH’s innovative Relearning methodology ensures professionals effectively develop their skills, maximizing practical knowledge updates in the treatment of Cancer of Unknown Primary.

You will analyze the genetic and epigenetic patterns of complex tumors through an agnostic approach”

This Master’s Degree in Cancer of Unknown Primary contains the most complete and up-to-date university program on the market. Its most notable features are:

• The development of practical case studies presented by experts in Medicine
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies in the management of the audiovisual industry
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

You will lead oncology teams, fostering collaboration among various specialists to optimize clinical decision-making and provide top-quality care”

The faculty includes medical professionals who bring their practical experience to the program, alongside renowned specialists from leading societies and prestigious universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive learning experience designed to prepare for real-life situations.

This program is designed around Problem-Based Learning, whereby the student must try to solve the different professional practice situations that arise throughout the program. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts.

You will apply innovative approaches for the personalized treatment of Cancer of Unknown Primary, using state-of-the-art sequencing tools"

You will select the most appropriate therapies to treat the tumor based on the latest scientific evidence and the most up-to-date clinical guidelines"

This innovative university program offers a detailed analysis of prognostic factors and therapeutic strategies in rare tumors, with a special focus on resistance mechanisms and second-line treatments. It also provides in-depth study of Nasopharyngeal Cancer, Salivary Gland Tumors, and even Melanomas. This will enable professionals to enhance their advanced skills in diagnosis, multidisciplinary treatment, and management of targeted therapies. As such, physicians will be able to personalize treatments based on the individual needs of patients and optimize their overall long-term well-being.

You will master cutting-edge bioinformatics tools to perform genetic analyses and characterize Tumors of Unknown Primary”

Module 1. The Reality of Orphan, Agnostic, and Cancer of Unknown Primary Tumors

1.1. Low Incidence Cancer

1.1.1. Uncommon, Rare and Ultra-rare Cancers
1.1.2. Orphan Tumors
1.1.3. Agnostic Tumors
1.1.4. Cancer of Unknown Primary

1.2. Epidemiology of Uncommon Cancer

1.2.1. Incidence and Prevalence of Uncommon Tumors
1.2.2. Trend of Rates at European Level

1.3. Survival Rates for Uncommon Tumors

1.3.1. Survival Data at European Level
1.3.2. Causes of Differences in Survival

1.4. Precision Medicine and Rare Tumors

1.4.1. Precision Medicine
1.4.2. Rationale for Precision Medicine in Uncommon Tumors
1.4.3. Clinical Experiences with Precision Medicine for Uncommon Tumors
1.4.4. Application of Genomics in the Diagnosis and Treatment of Uncommon Tumors

1.5. Models of Care for Uncommon Tumors

1.5.1. Tumor Registry
1.5.2. Expert Networks
1.5.3. Reference Units
1.5.4. Tumor Board Review

1.6. Role of the Biobank in Clinical Research

1.6.1. Biobanks
1.6.2. Legislative Regulation
1.6.3. The Biobank in the Management of Uncommon Tumors

1.7. Methodological Aspects of Clinical Research in Uncommon Tumors

1.7.1. Importance of Clinical Research in Uncommon Tumors
1.7.2. Research Difficulties in Uncommon Tumors
1.7.3. New Models of Clinical Trials
1.7.4. Bayesian Inference
1.7.5. Nanoscience Applied to Rare Tumors or Bioinformatics and New Mathematical Models for the Study of Rare Tumors

1.8. Legislation

1.8.1. European Framework
1.8.2. Regulatory Agencies

1.9. Access to Drugs

1.9.1. Access to Drugs
1.9.2. Off Label Therapies

1.10. Psychological and Social Aspects of Low-Incidence Tumors

1.10.1. Psychological Aspects of this Spectrum of Pathology
1.10.2. Social Issues Affecting the Uncommon Cancer Patient

Module 2. Molecular Biology Tools for the Agnostic Approach to Rare Cancer

2.1. Concepts of Molecular Oncology

2.1.1. Genetic Concepts
2.1.2. Epigenetic Concepts
2.1.3. crDNA Concepts
2.1.4. RNA Concepts

2.2. Tumor DNA Study I. Solid Biopsy

2.2.1. Genome
2.2.2. Exome
2.2.3. Sequencing Panels

2.3. Study of Tumor DNA II Fluid Biopsy

2.3.1. Available Platforms
2.3.2. Current Applications

2.4. Study of Germline DNA

2.4.1. Variants and Polymorphisms
2.4.2. Germline Alterations

2.5. Study of Messenger RNA

2.5.1. Transcriptome
2.5.2. Sequencing Panels (Nanostring)
2.5.3. Single Cell RNA

2.6. Epigenetics I. Methylome and Methylation Panels

2.6.1. Methyloma
2.6.2. Methylation Panels

2.7. Epigenetics II Non-Coding RNA, Chromatin Modifications

2.7.1. Long Non-Coding RNA
2.7.2. MicroRNA
2.7.3. Chromatin Remodeling

2.8. Functional Models I. Drug Sensing in Primary Cell Culture and Organoids
2.9. Molecular Biology in Immuno-Oncology I

2.9.1. Tumor Mutation Burden
2.9.2. Neoantigens
2.9.3. Microbiota
2.9.4. Adoptive Cell Therapy

2.10. Molecular Biology in Immuno-Oncology II. Functional Models

2.10.1. Coculture of Lymphocytes
2.10.2. Humanized Murine Methods

Module 3. Pleural, Mediastinal and Chest Wall Tumors: Lung Cancer As a Paradigm of New Rare Tumors. Head and Neck Cancer

3.1. Tumors of Pleural Origin: Mesothelioma

3.1.1. Introduction and Epidemiology
3.1.2. Etiology and Pathogenesis
3.1.3. Clinical Presentation
3.1.4. Diagnosis and Staging
3.1.5. Prognostic Factors
3.1.6. Treatment and Recommendations (Guidelines/Consensus)
3.1.7. Future Perspectives

3.2. Mediastinal Tumors: Thymoma and Thymic Carcinoma

3.2.1. Introduction and Epidemiology
3.2.2. Etiology and Pathogenesis
3.2.3. Clinical Presentation
3.2.4. Diagnosis and Staging
3.2.5. Prognostic Factors
3.2.6. Treatment and Recommendations (Guidelines/Consensus)
3.2.7. Future

3.3. Chest Wall Tumors

3.3.1. Introduction and Epidemiology
3.3.2. Etiology and Pathogenesis
3.3.3. Clinical Presentation
3.3.4. Diagnosis and Classification
3.3.5. Prognostic Factors
3.3.6. Treatment and Recommendations
3.3.7. Future

3.4. Pulmonary Neuroendocrine Tumors (NETs): Typical Carcinoid, Atypical Carcinoid, and Large Cell Carcinoma

3.4.1. Introduction and Epidemiology
3.4.2. Etiology and Pathogenesis
3.4.3. Clinical Presentation
3.4.4. Diagnosis and Classification
3.4.5. Prognostic Factors
3.4.6. Treatment and Recommendations
3.4.7. Future

3.5. Lung Cancer as a Paradigm for Personalized Medicine: Diagnostic Techniques and the Role of Liquid Biopsy

3.5.1. Introduction
3.5.2. Sample Types According to Diagnostic Approach
3.5.3. Sample Handling Optimization
3.5.4. Response Time and Report Characteristics
3.5.5. Tumor Heterogeneity: Role of Liquid Biopsy
3.5.6. Molecular Diagnostic Techniques: IHQ, FISH, RT-PCR, NGS
3.5.7. Guide Recommendations

3.6. Mutations: EGFR, BRAF, MET, KRAS

3.6.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
3.6.2. Prognostic Factors
3.6.3. First-Line Targeted Therapy
3.6.4. Resistance Mechanisms
3.6.5. Second-Line Therapy and Successive Lines
3.6.6. Role of Chemotherapy +/- Immunotherapy
3.6.7. Future

3.7. Translocations: ALK, ROS-1

3.7.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
3.7.2. Prognostic Factors
3.7.3. First-Line Targeted Therapy
3.7.4. Resistance Mechanisms
3.7.5. Second-Line Therapy and Successive Lines
3.7.6. Role of Chemotherapy +/- Immunotherapy
3.7.7. Future

3.8. Rearrangements/Amplifications: NTRK, RET, MET, HER-2

3.8.1. Introduction: Epidemiology, Patient Profile, Diagnostic Techniques and Brain Disease
3.8.2. Prognostic Factors
3.8.3. First-Line Targeted Therapy
3.8.4. Resistance Mechanisms
3.8.5. Second-Line Therapy and Successive Lines
3.8.6. Role of Chemotherapy +/- Immunotherapy
3.8.7. Future

3.9. Nasopharyngeal Carcinoma and Salivary Gland Tumors. Nasal and Paranasal Sinus Tumors

3.9.1. Nasopharyngeal Carcinoma

3.9.1.1. Introduction
3.9.1.2. Epidemiological Data
3.9.1.3. Etiology and Etiopathogenesis
3.9.1.4. Clinical Manifestations
3.9.1.5. Diagnostic Methods and Extension Diagnosis
3.9.1.6. Multidisciplinary Treatment

3.9.2. Salivary Gland Tumors

3.9.2.1. Major Salivary Gland Tumors
3.9.2.2. Minor Salivary Gland Tumors

3.9.3. Nasal and Paranasal Sinus Tumors

3.9.3.1. Epidemiology
3.9.3.2. Etiopathogeny, Histology and Natural History
3.9.3.3. Clinical, Diagnostic and Staging
3.9.3.4. Treatment

3.10. Melanomas, Sarcomas and Lymphoproliferative Syndromes of the Head and Neck. Rare Tumors. Ameloblastoma. Neuroendocrine Head and Neck Tumors

3.10.1. Head and Neck Melanoma

3.10.1.1. Etiologic, Epidemiologic and Clinical Factors
3.10.1.2. Diagnostic and Therapeutic Aspects
3.10.1.3. Special Presentations of Head and Neck Melanoma

3.10.2. Head and Neck Sarcomas

3.10.2.1. Etiopathogenesis and Epidemiology
3.10.2.2. Clinical Aspects
3.10.2.3. Diagnosis
3.10.2.4. Therapeutic Aspects

3.10.3. Lymphoproliferative Head and Neck Syndromes

3.10.3.1. Etiological Factors
3.10.3.2. Staging Procedures
3.10.3.3. Clinical Scheme of Lymphoid System Neoplasms

3.10.4. Dental Tumors

3.10.4.1. Odontogenic Tumor Classification

3.10.5. Ameloblastoma
3.10.6. Neuroendocrine Head and Neck Tumors

3.10.6.1. Neuroendocrine Carcinomas of Epithelial Origin
3.10.6.2. Atypical Carcinoid
3.10.6.3. Small Cell Neuroendocrine Carcinoma
3.10.6.4. Large Cell Neuroendocrine Carcinoma
3.10.6.5. Neuroendocrine Carcinoma of Neural Origin

Module 4. Uncommon Digestive Tumors. Digestive Neuroendocrine Tumors Thyroid Cancer

4.1. Small Intestine Tumors. Appendicular Tumors

4.1.1. Small Intestinal Tumors

4.1.1.1. Epidemiology. Risk Factors
4.1.1.2. Pathogenesis, Molecular Profile and Hereditary Syndromes
4.1.1.3. Clinical Characteristics. Histological Subtypes
4.1.1.4. Diagnosis and Staging Prognosis
4.1.1.5. Localized Disease Treatment. Monitoring
4.1.1.6. Treatment of Metastatic Disease

4.1.2. Appendicular Tumors

4.1.2.1. Epidemiology
4.1.2.2. Histology Staging
4.1.2.3. Clinical Presentation. Diagnosis
4.1.2.4. Localized Disease Treatment
4.1.2.5. Treatment of Metastatic Disease
4.1.2.6. Pseudomyxoma Peritoneum

4.2. Cancer of the Anal Canal

4.2.1. Epidemiology. Risk Factors
4.2.2. HPV, Genotypes Molecular Pathogenesis
4.2.3. Pathologic Anatomy. Staging
4.2.4. Clinical Presentation. Diagnosis
4.2.5. Treatment of Localized Disease. Monitoring
4.2.6. Treatment of Metastatic Disease. Immunotherapy

4.3. Tumors of the Liver and Intrahepatic Bile Ducts. Neoplasms of the Gallbladder and Extrahepatic Bile Ducts

4.3.1. Hepatocellular Carcinoma

4.3.1.1. Epidemiological Aspects
4.3.1.2. Diagnostic Process
4.3.1.3. Staging
4.3.1.4. Local Disease Management: Transplantation vs. Resection
4.3.1.5. Local Disease Management: Ablative Techniques
4.3.1.6. Management of Locally Advanced Disease

4.3.1.6.1. Radioembolization
4.3.1.6.2. Transarterial Chemoembolization
4.3.1.6.3. Radiotherapy

4.3.1.7. Treatment of Metastatic Disease

4.3.2. Biliary Tract Tumours

4.3.2.1. Characterization of the Three Entities that Make Up the Group
4.3.2.2. Epidemiological Aspects
4.3.2.3. Risk Factors
4.3.2.4. Clinical Expressivity
4.3.2.5. Diagnostic Aspects
4.3.2.6. Unresectability Criteria
4.3.2.7. Histological Aspects
4.3.2.8. Molecular Aspects. Molecular Classification
4.3.2.9. Described Genomic Alterations
4.3.2.10. Treatment of Localized Disease

4.3.2.10.1. Surgery
4.3.2.10.2. Adjuvant Criteria
4.3.2.10.3. Monitoring

4.3.2.11. Treating Advanced Stages of the Disease

4.3.2.11.1. Treatment of Locally Advanced Disease
4.3.2.11.2. Treatment of Metastatic Disease

4.3.2.12. Monitoring

4.4. Gastrointestinal Stromal Tumors (GIST)

4.4.1. Clinical and Epidemiological Aspects
4.4.2. Diagnostic Process of GIST

4.4.2.1. Radiology
4.4.2.2. Histology
4.4.2.3. Molecular Biology

4.4.3. Treatment of Localized Disease

4.4.3.1. Surgical Aspects
4.4.3.2. Prognostic Factors after Resection
4.4.3.3. Adjuvant Treatment
4.4.3.4. Neoadjuvant Therapy

4.4.4. Treating Advanced Stages of the Disease

4.4.4.1. Surgery in the Context of Advanced Disease
4.4.4.2. Systemic Treatment
4.4.4.3. Monitoring

4.5. Neuroendocrine Tumors: Small Intestinal Tumors

4.5.1. Epidemiology
4.5.2. Pathologic Anatomy. Histological Degree. Ki67 and Mitotic Index
4.5.3. Molecular Factors Biomarkers
4.5.4. Clinical Presentation. Carcinoid Syndrome
4.5.5. Diagnosis and Staging Prognosis
4.5.6. Localized Disease Treatment Monitoring
4.5.7. Treatment of Metastatic Disease Treatment of Hormonal Hypersecretion

4.6. Neuroendocrine Tumors: Pancreatic Tumors

4.6.1. Epidemiology
4.6.2. Pathologic Anatomy. Histological Degree
4.6.3. Molecular Factors Biomarkers
4.6.4. Clinical Presentation. Carcinoid Syndrome
4.6.5. Diagnosis and Staging Prognosis
4.6.6. Localized Disease Treatment Monitoring
4.6.7. Treatment of Metastatic Disease. Treatment of Hormonal Hypersecretion Syndromes
4.6.8. Advanced Line Treatment

4.7. Thyroid Cancer

4.7.1. Introduction
4.7.2. Incidence and Epidemiology
4.7.3. Clinical and Diagnostic Aspects
4.7.4. General Aspects of Treatment
4.7.5. Guidelines Recommendations and Level of Evidence

4.8. Differentiated Thyroid Cancer

4.8.1. Diagnosis, Pathological Anatomy and Molecular Biology
4.8.2. Staging and Risk Assessment
4.8.3. Primary Tumor Management
4.8.4. Management of Advanced Disease
4.8.5. Follow-Up and Long Survivors

4.9. Anaplastic Thyroid Cancer

4.9.1. Diagnosis, Pathological Anatomy and Molecular Biology
4.9.2. Staging and Risk Assessment
4.9.3. Primary Tumor Management
4.9.4. Management of Advanced Disease
4.9.5. Follow-Up and Long Survivors

4.10. Medullary Thyroid Cancer

4.10.1. Diagnosis, Pathological Anatomy and Molecular Biology
4.10.2. Staging and Risk Assessment
4.10.3. Primary Tumor Management
4.10.4. Management of Advanced Disease
4.10.5. Follow-Up and Long Survivors

Module 5. Uncommon Gynecologic Tumors. Rare Breast Tumors. Genitourinary Oncology of Uncommon Tumors

5.1. Rare Ovarian Cancer

5.1.1. Sex Cord Tumors
5.1.2. Granulosa Cell Tumor
5.1.3. Female Germ Cell Tumors
5.1.4. Ovary Sarcomas
5.1.5. Hereditary Ovarian Cancer

5.2. Uncommon Uterine Cancer

5.2.1. Adenosarcoma
5.2.2. Mixed Mullerian Tumor
5.2.3. Uterine Sarcoma
5.2.4. Hereditary Endometrial Carcinoma

5.3. Rare Cervix Cancer

5.3.1. Adenocarcinoma
5.3.2. Non-HPV-Associated Cervical Cancer
5.3.3. Cervical Sarcomas

5.4. Other Uncommon Tumors of the Gynecological Area

5.4.1. Vulvar Cancer
5.4.2. Vaginal Cancer

5.5. Rare Breast Tumors

5.5.1. Classification of Rare Breast Tumors
5.5.2. Diagnostic and Therapeutic Aspects

5.6. Germ Cell Tumors

5.6.1. General Aspects: Etiology and Epidemiology
5.6.2. Clinical Aspects and Classification
5.6.3. Diagnostic and Therapeutic Aspects for Germinal Tumors

5.7. Low Incidence Prostate Tumors

5.7.1. Adenocarcinoma with Histological Variants

5.7.1.1. Adenocarcinoma NOS
5.7.1.2. Adenocarcinoma of the Acinar Cells
5.7.1.3. Mucinous Adenocarcinoma
5.7.1.4. Signet Ring Adenocarcinoma
5.7.1.5. Adenocarcinoma with Neuroendocrine Differentiation
5.7.1.6. Oxyphilic Adenocarcinoma
5.7.1.7. Spindle Cell Adenocarcinoma
5.7.1.8. Lymphoepithelial Carcinoma

5.7.2. Squamous Cell Carcinoma with Histologic Variants

5.7.2.1. Squamous Carcinoma
5.7.2.2. Adenosquamous Carcinoma

5.7.3. Invasive Ductal Carcinoma

5.7.3.1. Cribriform Carcinoma
5.7.3.2. Solid Carcinoma NOS
5.7.3.3. Papillary Adenocarcinoma NOS

5.7.4. Transitional Cell Carcinoma
5.7.5. Salivary Gland-Like Tumors

5.7.5.1. Adenoid Cystic Carcinoma
5.7.5.2. Basaloid Carcinoma
5.7.5.3. Basal Cell Carcinoma

5.7.6. New Molecular Array in Prostate Cancer

5.8. Uncommon Tumors of the Bladder and Upper Urinary Tract

5.8.1. Transitional Cell Carcinoma
5.8.2. Squamous Carcinoma with Variants
5.8.3. Adenocarcinoma with Variants
5.8.4. Salivary Gland-Like Tumors
5.8.5. Molecular Subtypes of Bladder Cancer

5.9. Uncommon Renal Tumors

5.9.1. General Aspects of Non-Clear Cell Renal Cancers
5.9.2. Epidemiology and Etiopathogenesis
5.9.3. Classification of Non-Clear Cell Renal Tumors
5.9.4. Diagnosis and Treatment

5.10. Penile Cancer

5.10.1. Epidemiology and Etiopathogenesis
5.10.2. Clinical and Diagnostic Aspects
5.10.3. Penile Cancer Staging
5.10.4. Localized Disease
5.10.5. Locally Advanced and Metastatic Disease

Module 6. Hereditary Syndromes: from Biology to Clinical Application. Pediatric Tumors and Pediatric Tumors Occurring in Adults

6.1. Hereditary Predisposition to Endocrine and Neuroendocrine Tumors

6.1.1. Clinical Aspects
6.1.2. Molecular Aspects

6.2. Familial Melanoma and Genodermatosis

6.2.1. General Aspects
6.2.2. Clinical Aspects
6.2.3. Molecular Aspects

6.3. Neurofibromatosis. Li Fraumeni Syndrome

6.3.1. General Aspects of Neurofibromatosis
6.3.2. Clinical Aspects
6.3.3. Molecular Aspects
6.3.4. General Aspects of Li Fraumeni Syndrome
6.3.5. Clinical Aspects
6.3.6. Molecular Aspects

6.4. Hereditary Syndromes in Children

6.4.1. General Aspects
6.4.2. Clinical Aspects
6.4.3. Molecular Aspects

6.5. General Aspects of Pediatric Cancer

6.5.1. Epidemiology and Etiopathogenesis
6.5.2. Clinical Aspects of Pediatric Cancer
6.5.3. Diagnostic and Therapeutic Aspects
6.5.4. Molecular Biology and its Application to Pediatric Cancer

6.6. Intraocular Tumors

6.6.1. Medulloepithelioma
6.6.2. Retinoblastoma

6.7. Ocular Tumors in Children

6.7.1. Orbital Tumors

6.7.1.1. Rhabdomyosarcoma
6.7.1.2. Pleomorphic Adenoma of the Lacrimal Gland
6.7.1.3. Orbital Metastases

6.7.2. Intraocular Tumors

6.7.2.1. Rhabdomyosarcoma
6.7.2.2. Pleomorphic Adenoma of the Lacrimal Gland

6.8. Bone, Germ and Other Pediatric Tumors

6.8.1. Ewing Sarcoma
6.8.2. Germ Cell Tumors
6.8.3. Other Pediatric Tumors

6.9. Palliative Care for Children

6.9.1. Peculiar Aspects of PC for Children with Cancer

6.10. Pediatric Tumors in Adults

6.10.1. General Aspects of Pediatric Tumors in Adults
6.10.2. Classification of Development Tumors
6.10.3. Diagnostic Aspects
6.10.4. Treatment Difficulties
6.10.5. New Approaches in the Management of Pediatric Tumors Occurring in Adults: New Methodological Designs

Module 7. Musculoskeletal Tumors. Epithelial Cancer. Central Nervous System Tumors. Ocular Tumors

7.1. Bone and Soft Tissue Sarcomas: Classification, Characteristics, and Diagnostic Therapeutic Approach

7.1.1. General Information, Epidemiology
7.1.2. Etiopathogenesis and Classification
7.1.3. Clinical Aspects
7.1.4. Diagnostic and Therapeutic Aspects

7.2. Soft Tissue Sarcomas

7.2.1. Liposarcomas
7.2.2. Rhabdomyosarcoma
7.2.3. Leiomyosarcoma
7.2.4. Synovial Sarcoma
7.2.5. Angiosarcoma
7.2.6. Lymphangiosarcoma
7.2.7. Malignant Peripheral Nerve Sheath Tumor
7.2.8. Specific Soft Tissue Sarcomas

7.2.8.1. Complex Karyotype Sarcomas
7.2.8.2. Translocation-Specific Subtypes
7.2.8.3. Developmental Sarcomas
7.2.8.4. Alveolar Soft Tissue Sarcoma
7.2.8.5. Clear Cell Sarcoma
7.2.8.6. PEComa
7.2.8.7. Solitary Fibrous Tumor
7.2.8.8. Inflammatory Myofibroblastic Tumor
7.2.8.9. Desmoplastic Round Cell Tumor
7.2.8.10. Mesenchymal Tumors with Locally Aggressive Behavior

7.3. Skeletal Sarcomas

7.3.1. Chondrosarcoma
7.3.2. Fibrosarcoma
7.3.3. Clear Cell Sarcoma
7.3.4. Chordoma

7.4. Visceral Sarcomas

7.4.1. General Aspects of Low-Incidence Visceral Sarcomas
7.4.2. Visceral Sarcoma Classification
7.4.3. Diagnostic and Therapeutic Aspects
7.4.4. Molecular Aspects

7.5. Central Nervous System Tumors. Classification, Characteristics and Therapeutic Diagnostic Approach

7.5.1. Classification
7.5.2. Epidemiology and Etiopathogenesis
7.5.3. General Clinical Features
7.5.4. Diagnostic Algorithm
7.5.5. Therapeutic Approach

7.6. Central Nervous System Tumors: Oligodendrogliomas and Diffuse Astrocytic Tumors. Ependymal Tumors. Choroid Plexus Tumors. Neuronal and Mixed Glial-Neuronal Tumors

7.6.1. Oligodendrogliomas and Diffuse Astrocytic Tumors
7.6.2. Ependymal Tumors
7.6.3. Choroid Plexus Tumors
7.6.4. Neuronal and Mixed Glial-Neuronal Tumors

7.7. Pineal Region Tumors. Embryonal Tumors. Central Nervous System Lymphomas. Germ Cell Tumors. Selar Region Tumors. Miscellaneous

7.7.1. Pineal Region Tumors
7.7.2. Embryonal Tumors
7.7.3. Central Nervous System Lymphomas
7.7.4. Germ Cell Tumors
7.7.5. Selar Region Tumors
7.7.6. Miscellaneous

7.8. Malignant Skull Base Tumors: Craniopharyngioma and Solitary Fibrous Tumor/Hemangiopericytoma

7.8.1. Chordomas
7.8.2. Chondrosarcomas
7.8.3. Craneofaringioma
7.8.4. Solitary Fibrous Tumor: Hemangiopericytoma

7.9. Skin and Appendage Tumours

7.9.1. Classification, Characteristics and Therapeutic Diagnostic Approach
7.9.2. Tumors Originating in Benign Structures

7.9.2.1. Porocarcinoma
7.9.2.2. Hydradenocarcinoma
7.9.2.3. Spiradenocarcinoma
7.9.2.4. Cylindrocarcinoma

7.9.3. Analogous Glandular Tumors

7.9.3.1. Adenoid Cystic Carcinoma
7.9.3.2. Secretor Carcinoma
7.9.3.3. Apocrine Carcinoma
7.9.3.4. Cribriform Carcinoma
7.9.3.5. Malignant Mixed Tumor
7.9.3.6. Malignant Myoepithelioma

7.9.4. Hair Follicular Differentiation Tumors

7.9.4.1. Trichilemmal Carcinoma
7.9.4.2. Pilomatrical Carcinoma

7.9.5. Tumors Originating in the Facial Area

7.9.5.1. Mucinous Carcinoma
7.9.5.2. Histiocytoid Carcinoma
7.9.5.3. Endocrine Mucin-Producing Sweat Gland Carcinoma

7.9.6. Cutaneous Sarcoma

7.9.6.1. Atypical Fibroxanthoma
7.9.6.2. Angiosarcoma
7.9.6.3. Dermatofibrosarcoma Protuberans
7.9.6.4. Non-HIV Kaposi’s Sarcoma, Other Sarcomas

7.9.7. Miscellaneous

7.9.7.1. Microcystic Adrenal Carcinoma
7.9.7.2. Adenosquamous Carcinoma
7.9.7.3. Adenocarcinoma

7.10. Eye Tumors in Adults

7.10.1. Eyelid Tumors
7.10.2. Basal Cell Carcinoma
7.10.3. Epidermoid Carcinoma
7.10.4. Keratoacanthoma
7.10.5. Lentigo Maligna Melanoma
7.10.6. Conjunctival Tumors
7.10.7. Conjunctival Squamous Neoplasia
7.10.8. Conjunctival Melanoma
7.10.9. Anterior Uveal Melanocytic Tumors: Iris Melanoma
7.10.10. Posterior Uveal Melanocytic Tumors: Choroidal Melanoma
7.10.11. Choroidal Metastases
7.10.12. Orbital Metastases

Module 8. Agnostic Tumors

8.1. Concept of Agnostic Treatment: New Entities in Oncology

8.1.1. Concepts
8.1.2. Agency-Approved Agnostic Treatments
8.1.3. Agnostic Treatments under Development

8.2. Neurotrophic Tyrosine Receptor Kinase (NTRK) Family

8.2.1. NTRK Structure and Function
8.2.2. Algorithm for Identifying Patients with TRK Fusions
8.2.3. Clinical Spectrum of NTRK-Fused Tumors

8.3. Treatment with NTRK Inhibitors

8.3.1. General Aspects
8.3.2. Indications
8.3.3. Pivotal Test Results
8.3.4. Results in Clinical Practice
8.3.5. Toxicity of NTRK Inhibitors

8.4. Tumors with Microsatellite Instability

8.4.1. Significance of Microsatellite Instability
8.4.2. Algorithm for Identifying Patients with Microsatellite Instability
8.4.3. Clinical Spectrum of Unstable Tumors

8.5. Treatment of Tumors with Microsatellite Instability

8.5.1. General Aspects
8.5.2. Indications
8.5.3. Pivotal Test Results
8.5.4. Results in Clinical Practice

8.6. Towards Agnostic Treatment of Thoracic and Head Neck Tumors

8.6.1. General Aspects
8.6.2. Indications and Results
8.6.3. Toxicity

8.7. Towards Agnostic Treatment in Digestive Tumors

8.7.1. General Aspects
8.7.2. Indications and Results
8.7.3. Toxicity

8.8. Towards Agnostic Treatment in Urologic and Gynecologic Tumors

8.8.1. General Aspects
8.8.2. Indications and Results
8.8.3. Toxicity

8.9. Towards Agnostic Treatment in CNS Tumors

8.9.1. General Aspects
8.9.2. Indications and Results
8.9.3. Toxicity

8.10. The Development of Agnostic Treatment in Other Tumors

8.10.1. General Aspects
8.10.2. Indications and Results
8.10.3. Toxicity

Module 9. Cancer of Unknown Primary

9.1. Introduction and Epidemiology of Cancers of Unknown Primary

9.1.1. Incidence
9.1.2. Prevalence
9.1.3. Prognosis
9.1.4. Risk Factors

9.2. Clinical Spectrum of the Disease

9.2.1. Classification
9.2.2. Subgroups of Patients According to their Presentation

9.3. Anatomopathological Aspects of the Disease

9.3.1. General Considerations
9.3.2. Histology
9.3.3. Recommended Immunohistochemical Profile

9.4. Diagnosis of Cancers of Unknown Primary

9.4.1. Recommended Diagnostic Tests
9.4.2. Role of PET-CT
9.4.3. Diagnostic Algorithm

9.5. Cancer of Unknown Primary in the Molecular Era

9.5.1. Paradigm Shift
9.5.2. Molecular Profiles Oriented to Anatomical Origin
9.5.3. Molecular Profiling Aimed at Identifying Genomic Alterations

9.6. Classic Treatment for Cancers of Unknown Primary

9.6.1. Good Subgroup Prognosis
9.6.2. Poor Subgroup Prognosis

9.7. Targeted Therapy in the Molecular Era

9.7.1. Paradigm Shift: From Clinical to Molecular Biology
9.7.2. Molecular Profiles Oriented to Tumor Origin
9.7.3. Molecular Profiles Oriented to Therapeutic Targets

9.8. Clinical Trials: New Designs
9.9. Role of Tumor Registry. Clinical and Molecular Committees

9.9.1. Tumor Registry
9.9.2. Biobanks
9.9.3. Clinical and Molecular Committees

9.10. Guide Recommendations

Module 10. Supportive Care, Management of Antineoplastic Treatment Toxicity, Palliative Care, and Care of Long-Term Survivors with Low-Incidence Tumors

10.1. Increased Survival and Quality of Life Associated with Supportive Care in Cancer Patients

10.1.1. Quality of Life Evaluation in Oncology
10.1.2. Impact of Supportive Care Treatment on Quality of Life
10.1.3. Impact of Supportive Care Treatment on Survival

10.2. Treatment of Oncologic Pain and its Associated Symptoms

10.2.1. Baseline Pain in Cancer Patients
10.2.2. Incidental Pain in Cancer Patients
10.2.3. Types of Pain: Somatic, Visceral and Neuropathic
10.2.4. Diagnostic Pain Assessment
10.2.5. Pain Treatment 1st and 2nd Step
10.2.6. Opioid Treatment: Opioid Rotation
10.2.7. Opioid Treatment Toxicity
10.2.8. Adjuvant Drugs
10.2.9. Intervention Techniques
10.2.10. Non-Pharmacological Techniques

10.3. Antineoplastic Treatment Toxicity: Chemotherapy

10.3.1. Chemotherapy Mechanism of Action
10.3.2. Chemotherapy Toxicity Assessment
10.3.3. Most Common Toxicities

10.3.3.1. Digestive Toxicity
10.3.3.2. Skin and Mucosal Toxicity
10.3.3.3. Hematological Toxicity
10.3.3.4. Neurotoxicants
10.3.3.5. Cardiotoxicity
10.3.3.6. Nephrotoxicity

10.4. Antineoplastic Treatment Toxicity: Targeted Therapy

10.4.1. Mechanism of Action of Targeted Therapies
10.4.2. Toxicity Assessment of Targeted Therapy
10.4.3. Most Common Toxicities

10.4.3.1. Digestive Toxicity
10.4.3.2. Skin and Mucosal Toxicity
10.4.3.3. Hematological Toxicity
10.4.3.4. Toxic Hypertension Management
10.4.3.5. Cardiotoxicity
10.4.3.6. Thrombotic Events

10.5. Antineoplastic Treatment Toxicity: Immunotherapy

10.5.1. Immunotherapy Mechanism of Action
10.5.2. Immunotherapy Toxicity Assessment
10.5.3. Most Common Toxicities

10.5.3.1. Digestive Toxicity
10.5.3.2. Skin and Mucosal Toxicity
10.5.3.3. Respiratory Toxicity
10.5.3.4. Neurological Toxicity
10.5.4. Toxicity in Special Populations

10.6. Severe Toxicity of Oncological Treatment: Admission Criteria for Cancer Patients in the ICU

10.6.1. Severe Toxicity Spectrum in Patients Treated with Immunotherapy
10.6.2. Retreatments after Treatment-Limiting Toxicity
10.6.3. Cytokine Storm Syndrome
10.6.4. Severe Neurological Toxicity
10.6.5. Severe Respiratory Toxicity
10.6.6. Aspects Related to Admission to Intensive Care Units in Cancer Patients

10.7. End-of-Life Care. Concepts Associated with Terminal Patients. Palliative Sedation

10.7.1. Care Models for Palliative Care Patients
10.7.2. Terminal Illness Concept
10.7.3. Major End-of-Life Syndromes
10.7.4. Agony Diagnosis: Situation in the Final Days
10.7.5. Palliative Sedation

10.8. Long-Term Cancer Survivors: Monitoring Programs

10.8.1. Introduction and Definition of the Long-Term Cancer Survivor Concept
10.8.2. Survival Rates and Estimated Number of Long-Term Cancer Survivors
10.8.3. Monitoring Models of Long-Term Cancer Survivors

10.9. Long-Term Cancer Survivors. Most Common Sequelae

10.9.1. Identification of Long-Term Survivors’ Specific Problems
10.9.2. Healthcare and Non-Healthcare Demand

10.10. Special Situations: Long-Term Survivors with Disease, Long-Term Child and Adolescent Survivors

10.10.1. Sick Patients and Long-Term Survivors
10.10.2. Long-Term Surviving Teenager

You will improve your ability to analyze genetic mutations and epigenetic modifications, enabling highly accurate molecular classification”